Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients
- PMID: 19696217
- PMCID: PMC2758258
- DOI: 10.2215/CJN.03980609
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients
Abstract
Background and objectives: As a major component of uremic syndrome, cardiovascular disease is largely responsible for the high mortality observed in chronic kidney disease (CKD). Preclinical studies have evidenced an association between serum levels of indoxyl sulfate (IS, a protein-bound uremic toxin) and vascular alterations. The aim of this study is to investigate the association between serum IS, vascular calcification, vascular stiffness, and mortality in a cohort of CKD patients.
Design, setting, participants, & measurements: One-hundred and thirty-nine patients (mean +/- SD age: 67 +/- 12; 60% male) at different stages of CKD (8% at stage 2, 26.5% at stage 3, 26.5% at stage 4, 7% at stage 5, and 32% at stage 5D) were enrolled.
Results: Baseline IS levels presented an inverse relationship with renal function and a direct relationship with aortic calcification and pulse wave velocity. During the follow-up period (605 +/- 217 d), 25 patients died, mostly because of cardiovascular events (n = 18). In crude survival analyses, the highest IS tertile was a powerful predictor of overall and cardiovascular mortality (P = 0.001 and 0.012, respectively). The predictive power of IS for death was maintained after adjustment for age, gender, diabetes, albumin, hemoglobin, phosphate, and aortic calcification.
Conclusions: The study presented here indicates that IS may have a significant role in the vascular disease and higher mortality observed in CKD patients.
Figures
References
-
- Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36: S24– S30, 2000 - PubMed
-
- Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048– 1056, 2005 - PubMed
-
- Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938– 942, 2001 - PubMed
-
- Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol 19: 863– 870, 2008 - PubMed
-
- Maizel J, Six I, Slama M, Tribouilloy C, Sevestre H, Poirot S, Giummelly P, Atkinson J, Choukroun G, Andrejak M, Kamel S, Maziere JC, Massy ZA. Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation 119: 306– 313, 2009 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
